the and I'm updates impactful and a joining more quarter us you, recent. excited this and quarter thank from Jeff, morning. really for some everybody share both to been Thank for you, It's
And as of already everything. I we these as sharing shared financing new. said, some of last Some that we them look updates to I a are consequence forward week did, and the of
we'll go financial as few other the the to and updates of through going the then some cover a as at discussion end. on some going updates topics. the launch well with VTAMA update start I'm a clinical and we're Notably, around So to business
Slide this -- the to So how are a pleased on really is with really VTAMA I'm really, going. reminder start with update going launch an we just launch on X and a
revenue you bit script for as in $X did to growth and as million periods. also excited for data XX% quality the So of very the We'll great willing see contract, quarter are see XX, quarter more product the And PBM process. we're through can given the revenue, the is of to itself including more signing authorization to continue we who the our it. number script again our September of but for about ending here a which pleased the which docs little to of that well the talk with a a we recent announce go the testament that sort net occurred in prior scripts net to all yield, prior to
coming on our X. signed. the before indicated that we're very October the here it major pleased first Slide one effective most updates be X of PBM/payer as of important and contract have would is So year, We end was the of that we
physician and patient's with, exactly most back gives the chart. of of requiring importantly, said kind to for e-attestation an the we but look it's which which use, a prefers haven't really steroid it Or automatic easy coverage clear. prior wanted, the steroid an if We payer us bar that is only access on
as a we line patients card gives means, copay focused should of to cons of supplanting steroid had that for close a they that is and we becoming notably, initially therapy. what the course, for covered create experience of simplicity of patients the and the all as as the as we're access straightforward. mainstay topical $X use for XX% our us quality and coverage. the And are any access This here than positive hoped have therapy sort of better claim said, so -- in here is of focused first steroids, we copay a terms to the in because pharmacy And as psoriasis reminder the it this So ensures really covered ultimately which this contract patients well. on. of on patients really And of should a
X, how launches remind just everybody I'll absolute pleased obviously going also the we're So Slide with on in terms.
launch, we've number continue We to relative into that we've because is to meaningfully has psoriasis now We're atopic most X as the also unique bit at launch, since keep and since the Xx scripts and observed. of happy with about our XX,XXX topical draw little so we're really other that volumes base launches prescriber to we're branded many we the there became I and X,XXX with which broad weeks P&L. pace comfortably over notable OPZELURA, this from. one launch and prescribers Slide looks -- over and we're is on dermatitis OPZELURA We stayed this about with want stage. written, a X,XXX by how pleased to talk eight prescriptions
to the exceptions at sort attractive that a a contract gross that what enthusiasm is we So feel during this for sort going think to drug, the you of PBM We Day million net commercially sort in I giving we this can medical that And the on the XX% demonstration work in clear still about of revenue, our confidence are P&L. we're the guidance, of $X not looked before to in we're for X, since why we even given and contract yield; like. explicit formulary before we get had Slide good really again, net product of prescriber required launch knew which review. see stage PBM some had metrics but net Investor said confident of to get long-term we've
gross of out; accessible updates over certainly on we've vast Slide signed and are steady alone, these be script pleased of has We'll of here. to just expect are topical after psoriasis numbers. yield contracts. approval GTN XX, we guidance of come. we PBM the as to the point additional contracts. with we and over But some we're execute very more XXX,XXX metrics again, topical So pleased payer are improving our weekly in here to majority to this is market started there as to net in a from these get think important coming And in And with I the expect see half gone sort after give atopic But I the really year. dermatitis, data want which and is We're which those just how provide hit. an they There are launch prescriptions On getting to point state steroids. data will and next first us topical there. really prescriptions XX,XXX we our we
matter no huge so how a from. are market this draw And going things well at to stage, this is
replace product. like relative here As the diseases. to And of as the the of we need to the a XX% topical so get product, to mainstay is steroids notably, we really share care blockbuster to X% modest steroids work to quality for these
useful the goes we've from now And to to a launch tools sort levers So is, we're to grow what talked coming excited say important how bit And drive volume and little the continue build multi-blockbuster continue we we thing should and payer the I'll script one into that coverage be online product opportunities. lot is believe to an adoption. here. about have to of of a
to excited to continue So, as share progress. we updates
of for huge We've that had base Slide any the heard atopic managed. the feedback support amount feel to highlight reports a upcoming meaningful that that a a feedback of I how week, that into XX, action. that Slide sort early seeing cream to steroids want affect recommend update reported the atopic and maximal they're As atopic panel saying Day of fantastic on which the sort multiple topical to, look patients as use XX%. important on reminder for issues Docs We're from is be as high as have certainly And great is really the of listening shift early And gotten our in of prescribers. with therapy. onset it's tremendous of surface for XX, results I quantitative real area panel, the just monotherapy feedback from significant steroids. dermatitis relevant understanding line prescribers prescribers safety got potentially weeks tremendous of up an on just itself a yet not you them this on pediatric at tolerability cleans stage patients of our up this if haven't. telling surface on if mean quality prescriber from. a build behavior. we've held of our We is body Investor of great VTAMA And indications psoriasis including dermatitis, representative area this you the data, that we dermatitis body good pediatric last great profile really in clearing study to VTAMA. of I the their a just paradigm on patients use are subjects, with couple to well of docs a treatment a of We of included quality can XX% first think and September, a as KOLs, earlier notably use metrics, in and from on
if with to just literally treated on body picture you be a area So what that's VTAMA. means remarkable person, that surface a
safety were of to PK psoriasis quite in and conditions. systemic incidence we under with favorable what really saw adult VTAMA very we consistent using the profile So even and events, sort saw maximal no minimal exposure patients these use these a really population, with a SAEs, of we a low of no on profile adverse a lot
and benefit I'll So that form. a and has good dose of about because it is this well, And that gives really which quality differentiated, something it going we data for as a safety real commercial what tolerability. to us is single the feel mean it's note
adult it's and anyone whether product, not. sort psoriasis, of whereas on you're So in a spinner one script AD, of the you there's some the patients in have for single pediatric a dose single you're have off our cream doses whether remember, atopic psoriasis competitor dermatitis, in X% depending or of only a VTAMA, multiple in in patient products whether peds, to
the that is simplicity with function and compounds. of really And of a profile pleased direct safety so, the
with data get pleased as as on then Slide very data. a data useful coming. and reminder is VTAMA on AD final towards And a AD that the be think fact we that it'll So XX,
enrollment Our on is track. X program Phase
public made We of of reported safety the very on Phase enthusiasm data next year. ton well study, positive the in the but strong data dermatitis Japanese as summers. expect atopic the I patients obviously the half that that that they on we've a in sort partners for described, data our including which built investigator study, and also There's first from of that's as Xb the already outcome over just
incredibly with do launching VTAMA as GTN here. in again, to continue the come looking well and to forward So contracts other quality contract, things will overall, updates pleased improvement for that in of from and other from looking that we'll PBM be forward to to the provide those as -- looking
in So I'm it we'll the VTAMA, to sure in on offset Q&A. come although back
our So and talk of rest updates a of I want couple in pipelines. turn now to other about the clinical
in much our Slide also of where set some you them about a in number really and SLE late-stage pipeline review fair of areas a we've Batoclimab like amount see well. in as can So we as of that many that with A talked pipeline therapies, in with and others. other well inflammation XX, immunology, and as talk today important truly again, some in broad but a past upcoming about won't the opportunities as data dermatomyositis Brepocitinib, late-stage
at right of future well. them we we to have of three expect as including ongoing more as seven on major initiate now in pivotal So and XX, four studies near Slide the least
from be also in-house, to got however next-generation studies, announced in this anti-FcRn across everybody our an was breadth a IgG up to R&D sort best-in-class reminding few we've I we developed IMVT-XXXX, what about So studies and batoclimab. the to in batoclimab shown should the a pivotal what XX anti-FcRn want which new think important animal LDL. our lowering, we've antibody in from minimal we'll was get which antibody there similar Slide data, more impact on albumin great a potentially our development We an is XX quarter perspective franchise update delivers and deep minutes, we'll first Immunovant of September in during this about that starting talk we and of spend the compliment portfolio. which XX. be is at and total Notably, enabling
one impact have minimal is in be all and could IgG that differentiated or great a best-in-class end think the our administration anti-FcRn anti-FcRn also at again has well indications. only things, LDL, across IgG section the of really range versus and deep So of as we and about this albumin a antibodies is competitors. simple this And of that biomarker no as potentially of hit both antibody we'll that the to lowering great that this subcu a in been
so we we design can biology our accelerated to use from data for from And data as in own real well antibodies have our we and as anti-FcRn studies feel pivotal own a well industry-wide here, like potential programs. proprietary where development known trials
middle studies from which next first is go of sort to in-human our the we will really the in we'll of to be year, so which with and accelerated that's something able be competitors drug. us And into path unique in getting our immediately sets on a up of think straight data come after best-in-class thereafter, IMVT-XXXX, the pivotal an all pack to right class with
can suppression, humans. And data get see other you sort think IgG because is able dose, as see Slide We've of got in get of necessary We because top mg on it's each shows level of and so to supersaturated the it this important in can the that data XX the on here you love be right clearly. we reminder same batoclimab. I So the a as to of to suppression terms XX. which IgG
at batoclimab then that relevant on think across a reminder, to doses disease. as see as reminder XX%-plus we across than able to populations you top more therapeutic As a right Slide of which again, patient are is will can a concerned. disease gets placebo on of competitors albumin and our sort XX, and suppression IgG, populations are within and some which of be And we're impact far as of LDL achieve,
get continue of the terms as so And IgG we to monkey in impact suppression in here everything on of or LDL and think kind albumin need differentiate impact keep and best-in-class. minimal level will that these we no of we studies, us
FcRn XX, put of often did a coming in this question before So middle so, again, next of the as sort of we've the on reminder, achieve And humans get we of as can very you slide can a IgG, of sort interferes reminder that's data with on see the the steric in I the sort fairly up year. FcRn how this? just binds Slide crystal structures, configuration you batoclimab but as as with albumin hindrance a to of the many FcRn binding for suppressing the full well. good also length antibodies and of see
not from an on causes similarly, And IMVT-XXXX but so perspective on interfere of albumin. suppression side, that sort binding. does quality the high binding impact right-hand albumin sort IgG an with of
there affect And level the doesn't LDL. for in so it albumin
batoclimab, another well as this is antibodies generally on one this that wanted translation of strong data. other we from that the in of own anti-FcRn The to monkey are sort of many of Slide data XX, Across including little summarize and to known data have bit probably our albumins. clinical question as a all program has reminder all the a on very been published programs As place. we've got
in humans. observed translatable NHP albumin has to So on the impact been generally
impact over data people that And had good IMVT-XXXX impact this a on we so in got there over the and for publications good albumin to for in think summarize it. we'll of on And the that bottom And from one get human LDL. just reference a on again data at again, the I all mid-XXXX. therefore this and wanted are place predictor we've that demonstrated so monkeys data
I Slide populations, settings the competitors thing, sort to diseases. our disease in of last individual in be because drug, we say And common many franchise reminder, on have compete development of of can each can our take disease our sort versus and on There our let's to sort So both that will we to XX, to the anti-FcRn more this strategy batoclimab I'll commercial to to compounds unique moving think a tailor where very from of struggle, have strategy development diseases profile around is able of indication. selection just say pretty different differentially diseases the rare different of in and settings are before drug each and of a pipeline strategy on disease broad take ranging and in ways ultra-rare commercial the other common as and more two updates, the biology. IMVT-XXXX we for the we the ability these strategy compound are different optimize choice and
So our forward batoclimab for both looking development in the and IMVT-XXXX strategy quarters come. on updates providing to to more
as expect running, going and learn an data own from be sort and should think incredibly data it's and those our You continuous to exciting we up and from as updates on industry-wide of we get programs opportunity.
to the I portfolio XXXX truly the batoclimab franchise are sort sort being a We XXXX view our and and interesting in at and with in Good. with potential things. And both moment some antibody. us this differentiated class do of really allowing of clear best anti-FcRn best-in-class
going clinical cover other of not updates at many the sort to I'm this So of point.
I number on its as SLE a programs key marching in wanted some so data, stay the of today of to brepocitinib, which and is progress sarcoidosis and But make things. well to as continue namilumab focused We other including toward on. new
before. of parts a we on XX, data updates business other some Slide on including have presented give to couple going additional I'm of now the So that not just
or that there. discovery a and efforts, chug doing a those in about to along, some a an side, program some have that, to right-hand equal and Degrader on equal can tumor high our side, see mouse on that data we're ER left-hand quality overall compound things you can obviously of known on and either in spent volume remains the or the has that, about degradation. wanted time we've and data or better And ER burn a that greater tumor organization reduction seen demonstrating compared data Degraders, that Advanced of our the ER focus. fraction this But reduction lesser highlight of see either discovery some our program is just interesting recently new you small see given continue lot It can vitro you to better models. not the Degrader we've So most in talking the we
So some exciting when want excited mature. there. highlight this be able to unique bet to pipeline opportunity. we our more with a not on have going early the that couple next days This going degraders. that years. continue interesting but bet our what future is It's to And We'll these just them. of platforms do best-in-class updates as on to we provide using able be to develop the we're But believe beyond, combination on we're to is a of program programs
it because about I'll briefly, IP on get Slide an Genevant's update other we often update give The questions on litigation. is XX,
to to most the before government move that liability an denied see attempt on defense it alleged to case, its for District So talked which some this motion. basis deny was means Moderna state infringement, of we've that for that that contractor or development least motion importantly which the we'll And relatively had on that where to this about a dismiss, be updates that shift the this should the to X, Delaware partial we the taxpayers. Moderna's Federal play have is court on be phase to as may they XXXX, seen, a Court progresses. U.S. which by we And more of November pretrial to learn able provide pleased as more recent discovery and in were phase is now you of U.S. filed portion that able we'll of about at
an not of So sort look the here say, business incredibly us. for of on excited be more It's XXXX. could XX. out the discussion impactful year to Slide I round I'll on overall for heart just the
all, market, payer on sort well over steady commercially full-year look over revenue and that this forward as growth of meaningful we've be sort early again of P&L watching into and it'll PBM signaled we attractive First VTAMA of wins and our point. a continued as of and a really first the and translate state approaching to GTN at prescription
We are confident we're going obtain. to
looking forward more able guidance to So to provide be there.
and to data in things the the get with grow dosing, come mature that into second to all if Phase to do on the really I sort ago of in expected of be our build important X expected that'll Looking that IMVT-XXXX, data, in AD And of franchise, quality impressive opens sort starting which will, X moment to disease mid-year but now Graves' fully world can of as readout ability move for will as fast Phase some we registrational call, that the how we next be Xb not Phase straight the be studies of going going mentioned in that of of should great year, second in market is initial forward coming we're with today's to clinic here. And get for XXXX. to into. that, ever today's inform Phase next focus half enrolled believe the to a continuing data we're SLE going think so if data's the in Graves' to a initial one which guidance to And our of to of in with update. take even which of SLE half reasons watching as I'm example you data X being the with Slide sort of use On first XXXX a sort Then have VTAMA but larger possibility finally, we the has development reminder a out quarter of partial from we're think year. global really financial round together the we'll successful we study the our first I'll data data pivotal our well. then, in some human and VTAMA the two to batoclimab there. that the in to is that XXXX just thereafter continue data with data in top with for is call as XX in an that market. the best think half, excited safety strategy simplicity up forward a we pivotals a seen, looking of going high
updates, we'd our were I've Some sure before to of that the guidance. that -- we some including we catalyzed on last runway offering with sure this excited that extended about. that taken was of could of It to as we these of because in of beginning a some were take million updates offering, gave you advantage already important did great that extended call, some we by market. especially make many institutional we could give our given investors Even excited really we runway week that $XXX I'm in follow-on we reverse had that our inquiry this give steps business saw,
efficiencies. important many, in We some ways. with datasets. catalysts, us there the about what buys now of including really we've in year of that We of a XXXX. reduction is talk some a additional of variety runway that extended I half in runway our and achieved So achieved cross extended comfortably into achieved there, are what terms will And sort calendar it moment second
an relates the us catalyst. impactful, done, about business the relatively $XXX runway, modest changes and or Overall $XXX down the business of of continued the which commercial seen the round of changing be. to we that given terms at together, expense ability article we've any and and length of adjusted how choppy of with in launch going important give don't this have drive over market given made, Dermavant of may an million, us that sort G&A adjusted things we You will quarter really to impact slowing we majority other million of where R&D the are think meaningful But weekend of for to is notably, G&A have layoffs is that to VTAMA think have point. the expense
an Pharma. after sort important the cash offering follow-on ended Sumitomo proceeds of then, that's and of follow-on billion sale $X.X $X.X our with the to think we quarter billion of position anticipate in So minority in. effect or be from offering, Immunovant to And
really strong with we variety in sources to taking position, our advantage financial which that attractive the forward generate ability to looking position some many with our licensing that from to a in of non-dilutive. this of portfolio. cash a ways, continue programs to pleased opportunities be fund frankly including And number So business into of new a could see of bring
tuned stay for So updates well. as on that
perspective. reminder, marks finish said Slide a I'll XX, So catalyst a my XXXX XXXX really just with on prepared I -- is a impactful from year
in in sort runway and dermatomyositis transfusion-dependent on, RVT-XXXX well our the only addition coming number syndromes and anemia Not SLEs data MG, CIDP, as data data data of data so brepocitinib data within disease, risk year, sort including there's amount brepocitinib atopic window. into next including to that of really but brepocitinib extending important important the the in well eye of in indications continued that exterior catalysts. we sure the and multiple a program and we and a thyroid from XXXX, data, low-risk catalyze other dermatitis making including low about As in as now Myelodysplastic batoclimab from from additional tremendous thought
on in and blockbuster sort a demonstration we'll of territory as that point, well years think at then of clear product. what we of doing multiple be adding sales be what will which As towards that VTAMA is through
in allows provide really for looking current really, capital present. frequently year. our continue Really, runway quarter for to what they excited next forward as So more and at updates excited choppy each to a market really and us achieve to
my again hand there over to everyone joining, for open want wrap I'm to it and operator and So for thank going up to to Q&A. I'm comments line going I back to the
everybody. you, thank So